- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06010134
Osteogenesis Imperfecta and Balance
Efficacy of Whole Body Vibration on Balance and Motor Control in Children With Osteogenesis Imperfecta
Osteogenesis Imperfecta (OI), also known as brittle bone disease, is a group of genetic disorders that mainly affect the bones. It results in bones that break easily. Its severity may be mild to severe. Other symptoms may include a blue tinge to the whites of the eye, short height, loose joints, hearing loss, breathing problems and problems with the teeth.
Physiotherapy is aimed to strengthen muscles and improve motility in a gentle manner, while minimizing the risk of fracture, and the use of support cushions to improve posture.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study aimed to assess the efficacy of Whole Body Vibration on balance and motor function in children with Osteogenesis Imperfecta.
Whole body vibration (WBV) therapy is targeted at musculoskeletal strengthening and has been trialed in a variety of conditions. WBV has been shown to have therapeutic advantage in various osteopenic preclinical models and populations such as postmenopausal women (improved mobility, muscle strength, postural strength, and bone density) and children with osteogenesis imperfecta (improved mobility)
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nehad Abo-zaid, Assistant Professor
- Phone Number: +201008980727
- Email: dr.nehadahmed@svu.edu.eg
Study Locations
-
-
-
Qina, Egypt, 83523
- Recruiting
- South Valley University, Faculty of Physical Therapy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Their age was ranging from six to twelve years
- Children participated in this study were from both sexes
- All children with stable medical and psychological status.
- They were able to follow the verbal commands or instructions during testing.
Exclusion Criteria:
- Children with visual or auditory problems.
- Children with any cognitive problems.
- Children without deformity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Control Group
Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand pronator, wrist extensors, knee extensors and ankle dorsiflexors, coordination and balancing exercises.
|
Physical Therapy Program plus Whole Body Vibration
|
|
Experimental: Study group
Group 2 the study group received the same physical therapy program 15 min.
plus Whole Body Vibration for 15 min.
|
Physical Therapy Program plus Whole Body Vibration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Over All Stabiity Index
Time Frame: at day 0
|
Stability Index
|
at day 0
|
|
Over All Stabiity Index
Time Frame: at day 90
|
Stability Index
|
at day 90
|
|
Medio lateral Stabiity Index
Time Frame: at day 0
|
Stability Index
|
at day 0
|
|
Medio lateral Stabiity Index
Time Frame: at day 90
|
Stability Index
|
at day 90
|
|
Antro posterior Stabiity Index
Time Frame: at day 0
|
Stabiity Index
|
at day 0
|
|
Antro posterior Stabiity Index
Time Frame: at day 90
|
Stabiity Index
|
at day 90
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hanady Mohamed, Faculty of Physical Therapy, Benha University
Publications and helpful links
General Publications
- Andersen PE Jr, Hauge M. Osteogenesis imperfecta: a genetic, radiological, and epidemiological study. Clin Genet. 1989 Oct;36(4):250-5. doi: 10.1111/j.1399-0004.1989.tb03198.x.
- Folkestad L, Hald JD, Ersboll AK, Gram J, Hermann AP, Langdahl B, Abrahamsen B, Brixen K. Fracture Rates and Fracture Sites in Patients With Osteogenesis Imperfecta: A Nationwide Register-Based Cohort Study. J Bone Miner Res. 2017 Jan;32(1):125-134. doi: 10.1002/jbmr.2920. Epub 2016 Aug 29.
- Bishop N. Bone Material Properties in Osteogenesis Imperfecta. J Bone Miner Res. 2016 Apr;31(4):699-708. doi: 10.1002/jbmr.2835. Epub 2016 Mar 26.
- Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000 Jun;26(6):581-9. doi: 10.1016/s8756-3282(00)00269-6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P.T.REC/012/002577
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteogenesis Imperfecta
-
Ultragenyx Pharmaceutical IncMereo BioPharmaCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IV | Osteogenesis Imperfecta, Type IUnited States, Canada, Denmark, France, United Kingdom
-
Nationwide Children's HospitalCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IIUnited States
-
Emory UniversityNot yet recruitingOsteogenesis Imperfecta | Osteogenesis Imperfecta Type III
-
Angitia Biopharmaceuticals Guangzhou LimitedNot yet recruitingA Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR) (EIR)Osteogenesis Imperfecta (OI)China
-
Istituto Ortopedico RizzoliRecruitingOsteogenesis Imperfecta | Osteogenesis Imperfecta (OI)Italy
-
Novartis PharmaceuticalsCompletedOsteogenesis ImperfectaUnited States
-
Shriners Hospitals for ChildrenNovartisCompleted
-
University Hospital, GhentUniversity Ghent; Brittle Bone Society; Osteogenesis Imperfecta FederationRecruiting
-
AmgenTerminatedOsteogenesis Imperfecta (OI)Canada, Czechia, Spain, United Kingdom, United States, Italy, Hungary, Australia, Belgium, France, Germany, Poland
-
Angitia Incorporated LimitedRecruitingOsteogenesis Imperfecta (OI)United States, France, Netherlands, Australia, Denmark, United Kingdom, Canada, Argentina
Clinical Trials on Physical Therapy Program
-
Taif UniversityNot yet recruitingMovement Disorders
-
University of HaifaUnknownVestibulopathy, Acute PeripheralIsrael
-
Cairo UniversityCompletedSpastic Cerebral Palsy | Management | Serial Casting | Lower Limb DeformitiesEgypt
-
The Greater Poland Cancer CentreCompletedPhysical Therapy | Accessory Nerve InjuriesPoland
-
Ragaee Saeed MahmoudRecruiting
-
South Valley UniversityRecruiting
-
Philadelphia University, JordanRecruitingCerebral Palsy (CP) | Crouch Gait | Muscle Weakness | Patient | Diaplegia | Anterior Pelvic TiltJordan
-
Cairo UniversityNot yet recruitingHemiparetic Cerebral Palsy
-
University of AlbertaCanadian Institutes of Health Research (CIHR)RecruitingKnee Osteoarthritis | Hip OsteoarthritisCanada
-
Cairo UniversityCompleted